Home › Compare › BOTRF vs ABBV
BOTRF yields 4.35% · ABBV yields 3.06%● Live data
📍 BOTRF pulled ahead of the other in Year 3
Combined, BOTRF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BOTRF + ABBV for your $10,000?
China Everbright Water Limited, an investment holding company, provides water environmental management services in Mainland China and Germany. The company is involved in waste water treatment and reusable water; river restoration work; leachate and waste water treatment, as well as construction and maintenance of pipeline network; research and development, and consulting on water environmental technologies and treatment technology; and construction and operation of wetland ecological engineering projects. It also engages in the provision of business development and management services; survey, mapping, design, and consultancy for municipal projects; solar energy business; sponge city construction, operation, and research and development; and supply, construction, and operation of water supply facilities, as well as waste water source heat pumps. As of December 31, 2021, it invested in and operated water treatment projects with a designed daily waste water treatment capacity of approximately 7 million m3. The company is based in Shenzhen, the People's Republic of China. China Everbright Water Limited is a subsidiary of China Everbright Water Holdings Limited.
Full BOTRF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.